22
Dec
2016

Unfashionable Science, and a Daring Model for Alzheimer’s, Without VCs

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

If Trikafta Isn’t Good Enough for ICER, What Drug Is?